论文部分内容阅读
目的观察晚期非小细胞肺癌石蜡标本中ERCC1、Rad51和P53的表达,分析其与铂类药物化疗疗效的关系,为肺癌的个体化治疗提供依据。方法收集开封市第一人民医院2006年7月—2008年6月经病理组织学诊断的53例晚期非小细胞肺癌患者的病理学标本,用免疫组织化学的方法检测ERCC1、Rad51和P53的表达,所有的患者接受至少2周期顺铂或卡铂为主的化疗后,分析ERCC1、Rad51和P53蛋白的表达与化疗疗效关系。结果①53例患者中ERCC1、Rad51和P53阳性表达率分别是56.6%、43.4%和39.6%,其表达与患者的性别、年龄、体力状态、组织学类型及分期无关(P>0.05)。②ERCC1阳性组化疗有效率为41.6%,ERCC1阴性组化疗有效率为72.2%;Rad51阳性组化疗有效率为32.5%,Rad51阴性组化疗有效率为的表达为59.8%;P53阳性组化疗有效率为29.2%,P53阴性组化疗有效率为43.4%,差异均有统计学意义(P<0.05)。结论 ERCC1、Rad51和P53对化疗疗效的预测为负相关。
Objective To observe the expression of ERCC1, Rad51 and P53 in paraffin-embedded specimens of advanced non-small cell lung cancer and analyze the relationship between the expression of ERCC1 and the efficacy of chemotherapy in platinum-based chemotherapy for the individualized treatment of lung cancer. Methods The pathological specimens of 53 patients with advanced non-small cell lung cancer diagnosed by Pathology and Histology from the First People’s Hospital of Kaifeng City from July 2006 to June 2008 were collected. The expressions of ERCC1, Rad51 and P53 were detected by immunohistochemistry, All patients received at least 2 cycles of cisplatin or carboplatin-based chemotherapy, analysis of ERCC1, Rad51 and P53 protein expression and the relationship between the efficacy of chemotherapy. Results ① The positive rates of ERCC1, Rad51 and p53 in 56 patients were 56.6%, 43.4% and 39.6%, respectively. The expression of ERCC1, Rad51 and P53 was not related to sex, age, physical status, histological type and stage of patients (P> 0.05). ② The positive rate of chemotherapy in ERCC1-positive group was 41.6%, that of ERCC1-negative group was 72.2%, that of Rad51-positive group was 32.5%, that of Rad51-negative group was 59.8%, and that of P53-positive group was 29.2%, P53 negative group chemotherapy efficiency was 43.4%, the difference was statistically significant (P <0.05). Conclusions ERCC1, Rad51 and P53 are negatively correlated with the prediction of response to chemotherapy.